Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction
This comprehensive review argues that hallucinogenic drugs can enhance fear extinction—by promoting neuroplasticity, tempering amygdala hyperreactivity and facilitating emotional engagement—and thus offer advantages over current first‑line treatments for fear‑related disorders. It highlights MDMA and ketamine as the most promising therapeutics to augment exposure therapy and examines the molecular mechanisms relevant to hallucinogen‑assisted psychotherapy.
Authors
- Glavonic, E.
- Mitic, M.
- Adzic, M.
Published
Abstract
Fear‐related disorders, mainly phobias and post‐traumatic stress disorder, are highly prevalent, debilitating disorders that pose a significant public health problem. They are characterized by aberrant processing of aversive experiences and dysregulated fear extinction, leading to excessive expression of fear and diminished quality of life. The gold standard for treating fear‐related disorders is extinction‐based exposure therapy (ET), shown to be ineffective for up to 35% of subjects. Moreover, ET combined with traditional pharmacological treatments for fear‐related disorders, such as selective serotonin reuptake inhibitors, offers no further advantage to patients. This prompted the search for ways to improve ET outcomes, with current research focused on pharmacological agents that can augment ET by strengthening fear extinction learning. Hallucinogenic drugs promote reprocessing of fear‐imbued memories and induce positive mood and openness, relieving anxiety and enabling the necessary emotional engagement during psychotherapeutic interventions. Mechanistically, hallucinogens induce dynamic structural and functional neuroplastic changes across the fear extinction circuitry and temper amygdala's hyperreactivity to threat‐related stimuli, effectively mitigating one of the hallmarks of fear‐related disorders. This paper provides the first comprehensive review of hallucinogens' potential to alleviate symptoms of fear‐related disorders by focusing on their effects on fear extinction and the underlying molecular mechanisms. We overview both preclinical and clinical studies and emphasize the advantages of hallucinogenic drugs over current first‐line treatments. We highlight 3,4‐methylenedioxymethamphetamine and ketamine as the most effective therapeutics for fear‐related disorders and discuss the potential molecular mechanisms responsible for their potency with implications for improving hallucinogen‐assisted psychotherapy.
Research Summary of 'Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction'
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typemeta
- Journal
- Compound
- Topics
- APA Citation
Glavonic, E., Mitic, M., & Adzic, M. (2022). Hallucinogenic drugs and their potential for treating fear-related disorders: Through the lens of fear extinction. Journal of Neuroscience Research, 100(4), 947-969. https://doi.org/10.1002/jnr.25017
Cited By (1)
Papers in Blossom that reference this study
Stoliker, D., Egan, G. F., Friston, K. J. et al. · Pharmacological Reviews (2022)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.